Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Loxo Oncology CS (LOXO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,899,090
  • Shares Outstanding, K 29,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -72,400 K
  • 36-Month Beta 2.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.71 +24.89%
on 01/04/18
104.01 -0.68%
on 01/22/18
+16.30 (+18.74%)
since 12/22/17
3-Month
71.45 +44.58%
on 11/29/17
104.01 -0.68%
on 01/22/18
+16.68 (+19.26%)
since 10/20/17
52-Week
36.75 +181.09%
on 01/24/17
104.01 -0.68%
on 01/22/18
+63.89 (+162.12%)
since 01/20/17

Most Recent Stories

More News
Watch for Loxo Oncology In to Potentially Pullback After Gaining 6.09% Yesterday

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $97.50 to a high of $104.01. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high...

LOXO : 103.30 (+6.68%)
Roche (RHHBY) Clinches $1.7-Billion Deal to Acquire Ignyta

Roche (RHHBY) is set to acquire Ignyta for $27 per share or a total value of $1.7 billion to strengthen its oncology pipeline further.

BAYRY : 32.5750 (+1.64%)
LOXO : 103.30 (+6.68%)
RHHBY : 30.7900 (+0.33%)
RXDX : 26.90 (-0.19%)
Loxo Oncology In Set to Possibly Pullback After Yesterday's Rally of 4.05%

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $84.00 to a high of $87.18. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high...

LOXO : 103.30 (+6.68%)
Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers

Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO) has initiated the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...

LOXO : 103.30 (+6.68%)
Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers

Bayer and Loxo Oncology, Inc., (NASDAQ: LOXO), today announced updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT trial (NCT02637687). These data are being presented today...

LOXO : 103.30 (+6.68%)
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers

- 94 Percent of All Pediatric Patients Remain on Larotrectinib or Received Surgery with Curative Intent -

LOXO : 103.30 (+6.68%)
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195

Research Desk Line-up: Acceleron Pharma Post Earnings Coverage

LOXO : 103.30 (+6.68%)
XLRN : 44.50 (+3.39%)
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer

Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.

RARE : 53.39 (+8.60%)
ACHN : 3.01 (+0.67%)
VRTX : 161.91 (+2.49%)
DVAX : 17.00 (+8.63%)
LOXO : 103.30 (+6.68%)
AMGN : 192.33 (+1.61%)
ZYME : 10.04 (-2.33%)
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

- Up to $1.55B in Upfront, Regulatory, and Commercial Milestones -

LOXO : 103.30 (+6.68%)
Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer

Bayer announced today that the company has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut (NASDAQ: LOXO) for the development...

LOXO : 103.30 (+6.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.

See More

Key Turning Points

2nd Resistance Point 108.11
1st Resistance Point 105.71
Last Price 103.30
1st Support Level 99.20
2nd Support Level 95.09

See More

52-Week High 104.01
Last Price 103.30
Fibonacci 61.8% 78.32
Fibonacci 50% 70.38
Fibonacci 38.2% 62.44
52-Week Low 36.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.